Ordering
Available Variants10 mL
CHA.44640-10mL
Price
€125.60
Available – Dispatch in 14 days
250 mg
CHA.44640-250mg
Price
€186.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mL | CHA.44640-10mL | €125.60 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
250 mg | CHA.44640-250mg | €186.00 |
97% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C69H8 |
|---|---|
| CAS Number | 186682-36-0 |
| Molecular Weight | 836.80 |
| MDL number | MFCD00093802 |
| NACRES | NA.23 |
| UNSPSC Code | 12352103 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
ICMA, also known as 4-iodo-N-methyl-N-(1-methylethyl)benzeneamine, is a chemical compound with the CAS registry number 937-63-3. It is a research chemical that has been studied for its potential effects on the brain and nervous system. ICMA is structurally related to other compounds that have been investigated for their psychoactive properties. The compound has been synthesized and characterized in various scientific studies, which have examined its chemical and pharmacological properties. Research on ICMA is ongoing, and its potential applications and effects are still being explored. Further studies are needed to fully understand the properties and potential uses of ICMA, and to determine its safety and efficacy in various contexts. ICMA is not currently approved for use as a pharmaceutical or therapeutic agent.
